March 16, 2025  Home  |  About Us  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages  |  Contact Us  |  中文
HeBei Med  2023, Vol. 29 Issue (10): 1725-1730    DOI: 10.3969/j.issn.1006-6233.2023.10.027
Current Issue | Archive | Adv Search |
Short-Term Efficacy and Safety of Levosimendan in the Treatment of Patients with Acute Decompensated Heart Failure
HU Leyi, ZHOU Shu, CHENG Jinglin, et al
The Second Affiliated Hospital of Anhui Medical University, Anhui Hefei 230601, China
Download: PDF (1203 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  Objective: To analyze and study the results and clinical safety of a treatment regimen of conventional drugs combined with levosimendan in hospitalized patients with acute decompensated heart failure (ADHF) over a short course of treatment. Methods: A total of 160 patients with ADHF admitted to the Second Affiliated Hospital of Anhui Medical University from July 2018 to July 2022 were selected and divided into control group with conventional medication and experimental group with levosimendan combined with conventional medication, 80 cases in each group. Left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD) , N-terminal pro-B-type natriuretic peptide(NT-proBNP) , cardiac troponin I (cTnI), and cardiac functional grading were collected at admission and one week after treatment. At the same time, the therapeutic effect was analyzed and evaluated. Results: After treatment, LVEF levels of all subjects increased( both P<0.05 ). There were a significant decrease in the level of LVEDD、NT-proBNP、cTnI for both groups compared with those before treatment( both P<0.05 ). After the treatment of levosimendan, the magnitude of changes in LVEF, LVEDD, NT-proBNP and cTnI of the patients in the experimental group was better than that in the control group, and the difference between the two groups was significant (all P<0.05). Conclusion: Levosimendan in combination with conventional drugs improves myocardial function and slows down clinical symptoms in hospitalized patients with acute decompensated heart failure, and is safe and effective.
Key wordsAcute decompensated heart failure      Levosimendan      Left ventricular ejection fraction      Efficacy     
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
HU Leyi
ZHOU Shu
CHENG Jinglin
et al
Cite this article:   
HU Leyi,ZHOU Shu,CHENG Jinglin, et al. Short-Term Efficacy and Safety of Levosimendan in the Treatment of Patients with Acute Decompensated Heart Failure[J]. HeBei Med, 2023, 29(10): 1725-1730.
URL:  
http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.10.027     OR     http://www.hbyxzzs.cn/EN/Y2023/V29/I10/1725
Copyright © Editorial Board of HeBei Med
Supported by:Beijing Magtech